Pediatric Status Epilepticus Medication
- Author: Grace M Young, MD; Chief Editor: Richard G Bachur, MD more...
Medication Summary
Benzodiazepines, hydantoins, and barbiturates have anticonvulsant properties. Choose a parenteral preparation with rapid onset and long duration of action with the least amount of sedation and respiratory depression. Titrate for clinical response by waiting an adequate length of time for attainment of therapeutic levels in the brain.
Benzodiazepines
Class Summary
By increasing the action of GABA, which is a major inhibitory neurotransmitter in the brain, may depress all levels of CNS, including limbic and reticular formation.
In one study, no difference in efficacy was observed between caregiver-administered intranasal midazolam and rectal diazepam for terminating sustained seizures (ie, >5 minutes) in children at home. Caregiver's satisfaction was higher with the inhaled midazolam (easier to administer) and the median time from medication administration to seizure cessation was 1.3 minutes less for inhaled midazolam compared with rectal diazepam.[4]
Lorazepam (Ativan)
Sedative hypnotic with short onset of effects and relatively long half-life.
Preferred over diazepam because of significantly longer duration of action and equivalent rapid onset of action.
Important to monitor patient's blood pressure after administering dose. Adjust prn.
Diazepam (Valium)
For treatment of seizures. Depresses all levels of CNS (eg, limbic and reticular formation), possibly by increasing GABA activity. Effective for prehospital use as PR administration. Has a long half-life but rapidly redistributes from the CNS. Requires administration of the longer-acting phenytoin or phenobarbital because of very short duration of seizure control.
Do not administer >1-2 mg/min IVP in children or > 5 mg/min in adults.
Midazolam (Versed)
Used as alternative in termination of refractory status epilepticus. Because midazolam is water soluble, takes approximately 3 times longer than diazepam to peak EEG effects. Thus, clinician must wait 2-3 min to fully evaluate sedative effects before initiating procedure or repeating dose. DOC for child without immediate IV or IO access (available IM).
Barbiturates
Class Summary
These agents suppress CNS from reticular activating system (presynaptic and postsynaptic).
Phenobarbital (Barbita, Luminal)
Effective for febrile and neonatal status epilepticus. Can be administered PO. In status epilepticus, it is important to achieve therapeutic levels as quickly as possible. IV dose may require approximately 15 min to attain peak levels in the brain. If injected continuously until convulsions stop, brain concentrations may continue to rise and can exceed that required to control seizures resulting in subsequent toxicity. Important to use minimal amount required and wait for anticonvulsant effect to develop before administering a second dose.
If IM route chosen, administer into areas with little risk of encountering a nerve trunk or major artery such as one of the large muscles (eg, gluteus maximus, vastus lateralis). A permanent neurologic deficit may result from injecting into or near peripheral nerves.
Restrict IV use to conditions in which other routes are not possible, either because patient is unconscious or because prompt action is required.
IV administration should be < 50 mg/min. Parental product contains 68% propylene glycol.
Ensure monitoring for hypotension, bradycardia, and arrhythmias upon administration.
Hydantoins
Class Summary
These agents stabilize neuronal membranes and decrease seizure activity.
Fosphenytoin (Cerebyx)
Diphosphate ester salt of phenytoin that acts as water-soluble prodrug of phenytoin. Following administration, plasma esterases convert fosphenytoin to phosphate, formaldehyde, and phenytoin.
To avoid need to perform molecular weight-based adjustments when converting between fosphenytoin and phenytoin sodium doses, express dose as phenytoin sodium equivalents (PE). Although can be administered IV and IM; IV route is route of choice and should be used in emergency situations.
Concomitant administration of an IV benzodiazepine usually is necessary to control status epilepticus. Full antiepileptic effect, whether administered as fosphenytoin or parenteral phenytoin, is not immediate. Not currently recommended for acute control of status epilepticus because of its slow onset of action. Prepare drug in 100 mL of NS or D5W.
Phenytoin (Dilantin)
May act in motor cortex where may inhibit spread of seizure activity. Activity of brain stem centers responsible for tonic phase of grand mal seizures also may be inhibited. Effective for idiopathic, posttraumatic, focal, and psychomotor status epilepticus. Individualize doses. Administer larger dose before retiring if dose cannot be divided equally.
Administer only in saline solutions (incompatible when mixed with dextrose-containing solutions).
General anesthetics
Class Summary
All children must be intubated and paralyzed and must have continuous cardiorespiratory and EEG monitoring in a pediatric critical care unit. Pentobarbital may be required when seizures persist despite appropriate administration of other antiseizure agents.
Pentobarbital (Nembutal)
Short-acting barbiturate with sedative, hypnotic, and anticonvulsant properties. Can produce all levels of CNS mood alteration. Acts primarily on cerebral cortex and reticular formation through decreased neuronal synaptic activity.
Mitchell WG. Status epilepticus and acute serial seizures in children. J Child Neurol. Jan 2002;17 Suppl 1:S36-43. [Medline].
Brevoord JC, Joosten KF, Arts WF, van Rooij RW, de Hoog M. Status epilepticus: clinical analysis of a treatment protocol based on midazolam and phenytoin. J Child Neurol. Jun 2005;20(6):476-81. [Medline].
Papavasiliou AS, Kotsalis C, Paraskevoulakos E, Karagounis P, Rizou C, Bazigou H. Intravenous midazolam in convulsive status epilepticus in children with pharmacoresistant epilepsy. Epilepsy Behav. Apr 2009;14(4):661-4. [Medline].
Holsti M, Dudley N, Schunk J, Adelgais K, Greenberg R, Olsen C, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med. Aug 2010;164(8):747-53. [Medline].
Appleton R, Choonara I, Martland T,et al. The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, Members of the Status Epilepticus Working Party. Arch Dis Child. Nov 2000;83(5):415-9. [Medline].
Arzimanoglou A. Outcome of status epilepticus in children. Epilepsia. 2007;48 Suppl 8:91-3. [Medline].
Bassin S, Smith TL, Bleck TP. Clinical review: status epilepticus. Crit Care. Apr 2002;6(2):137-42. [Medline].
Chin RF, Neville BG, Peckham C, et al. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet. Jul 15 2006;368(9531):222-9. [Medline].
Choudhery V, Townend W. Best evidence topic reports. Lorazepam or diazepam in paediatric status epilepticus. Emerg Med J. Jun 2006;23(6):472-3. [Medline].
Epilepsy Foundation of America's Working Group on Status Epilepticus. Treatment of convulsive status epilepticus. JAMA. Aug 18 1993;270(7):854-9. [Medline].
Hanhan UA, Fiallos MR, Orlowski JP. Status epilepticus. Pediatr Clin North Am. Jun 2001;48(3):683-94. [Medline].
Kalviainen R, Eriksson K, Parviainen I. Refractory generalised convulsive status epilepticus: a guide to treatment. CNS Drugs. 2005;19(9):759-68. [Medline].
Korff CM, Nordli DR Jr. Diagnosis and management of nonconvulsive status epilepticus in children. Nat Clin Pract Neurol. Sep 2007;3(9):505-16. [Medline].
Lang ES, Andruchow JE. Evidence-based emergency medicine. What is the preferred first-line therapy for status epilepticus?. Ann Emerg Med. Jul 2006;48(1):98-100. [Medline].
Manno EM. New management strategies in the treatment of status epilepticus. Mayo Clin Proc. Apr 2003;78(4):508-18. [Medline].
Meierkord H. The risk of epilepsy after status epilepticus in children and adults. Epilepsia. 2007;48 Suppl 8:94-5. [Medline].
Neville BG, Chin RF, Scott RC. Childhood convulsive status epilepticus: epidemiology, management and outcome. Acta Neurol Scand Suppl. 2007;186:21-4. [Medline].
Novorol CL, Chin RF, Scott RC. Outcome of convulsive status epilepticus: a review. Arch Dis Child. Nov 2007;92(11):948-51. [Medline].
Pellock JM. Overview: definitions and classifications of seizure emergencies. J Child Neurol. May 2007;22(5 Suppl):9S-13S. [Medline].
Prasad AN, Seshia SS. Status epilepticus in pediatric practice: neonate to adolescent. Adv Neurol. 2006;97:229-43. [Medline].
[Best Evidence] Prasad K, Al-Roomi K, Krishnan PR, Sequeira R. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. 2005;CD003723. [Medline].
Raspall-Chaure M, Chin RF, Neville BG, Bedford H, Scott RC. The epidemiology of convulsive status epilepticus in children: a critical review. Epilepsia. Sep 2007;48(9):1652-63. [Medline].
Riviello JJ Jr, Ashwal S, Hirtz D, et al. Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. Nov 14 2006;67(9):1542-50. [Medline].
Rosenow F, Hamer HM, Knake S. The epidemiology of convulsive and nonconvulsive status epilepticus. Epilepsia. 2007;48 Suppl 8:82-4. [Medline].
Saz EU, Karapinar B, Ozcetin M, et al. Convulsive status epilepticus in children: Etiology, treatment protocol and outcome. Seizure. Dec 30 2010;[Medline].
Scott RC, Kirkham FJ. Clinical update: childhood convulsive status epilepticus. Lancet. Sep 1 2007;370(9589):724-6. [Medline].
Stephenson JB. Childhood convulsive status epilepticus. Lancet. Oct 14 2006;368(9544):1327-8; author reply 1328. [Medline].
Sugai K. Treatment of convulsive status epilepticus in infants and young children in Japan. Acta Neurol Scand Suppl. 2007;186:62-70. [Medline].
Sugai K. Treatment of convulsive status epilepticus in infants and young children in Japan. Acta Neurol Scand. Apr 2007;115(4 Suppl):62-70. [Medline].
Treiman DM. Treatment of convulsive status epilepticus. Int Rev Neurobiol. 2007;81:273-85. [Medline].
Yoshikawa H, Yamazaki S, Abe T, Oda Y. Midazolam as a first-line agent for status epilepticus in children. Brain Dev. Jun 2000;22(4):239-42. [Medline].

